Efficacy of anti-Trop-2-SN-38 antibody drug conjugates for therapy of tumors relapsed/refractory to checkpoint inhibitors

• 收藏
• 分享

专利权人:

Immunomedics; Inc.

发明人:

Govindan, Serengulam V.,Goldenberg, David M.

申请号：

AU2017257254

公开号：

AU2017257254A1

申请日:

2017.04.18

申请国别(地区):

AU

年份:

2018

代理人:

摘要：

The present invention relates to therapeutic ADCs comprising SN-38 attached to an anti-Trop-2 antibody or antigen-binding antibody fragment, more particularly sacituzumab govitecan. The ADC is administered to a subject with a Trop-2 positive cancer that is resistant to or relapsed from prior treatment with a checkpoint inhibitor. The therapy is effective to treat cancers that are resistant to checkpoint inhibitors.

来源网站：

中国工程科技知识中心

来源网址：

http://www.ckcest.cn/home/